Small molecule c-jun-N-terminal kinase inhibitors protect dopaminergic neurons in a model of Parkinson's Disease

ACS Chemical Neuroscience

Volumn 2, Issue 4, 2011, Pages 198-206

  Chambers, Jeremy W ^a   Pachori, Alok ^a   Howard, Shannon ^a   Ganno, Michelle ^a   Hansen, Donald ^a   Kamenecka, Ted ^a   Song, Xinyi ^a   Duckett, Derek ^a   Chen, Weimin ^a   Ling, Yuan Yuan ^a   Cherry, Lisa ^a   Cameron, Michael D ^a   Lin, Li ^a   Ruiz, Claudia H ^a   Lograsso, Philip ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

JNK; MPTP; neuroprotection; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIPARKINSON AGENT; BIOLOGICAL MARKER; PROTEIN C JUN; SR 3306; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SINGLE DRUG DOSE;

RODENTIA;

EID: 79955111737     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn100109k     Document Type: Article

References (32)

1. Dauer, W. and Przedborski, S. (2003) Parkinson's disease: mechanisms and models Neuron 39, 889-909 (Pubitemid 37130207)
2. Lang, A. E. and Lozano, A. M. (1998) Parkinson's disease. First of two parts N. Engl. J. Med. 339, 1044-1053 (Pubitemid 28457867)
3. Lang, A. E. and Lozano, A. M. (1998) Parkinson's disease. Second of two parts N. Engl. J. Med. 339, 1130-1143 (Pubitemid 28465762)
4. Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., Langston, W., Melamed, E., Poewe, W., Stocchi, F., and Tolosa, E. (2009) A double-blind, delayed-start trial of rasagiline in Parkinson's disease N. Engl. J. Med. 361, 1268-1278
5. Hunot, S., Vila, M., Teismann, P., Davis, R. J., Hirsch, E. C., Przedborski, S., Rakic, P., and Flavell, R. A. (2004) JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease Proc. Natl. Acad. Sci. U.S.A. 101, 665-670 (Pubitemid 38084694)
6. Xia, X. G., Harding, T., Weller, M., Bieneman, A., Uney, J. B., and Schulz, J. B. (2001) Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease Proc. Natl. Acad. Sci. U.S.A. 98, 10433-10438 (Pubitemid 32803037)
7. Wang, W., Shi, L., Xie, Y., Ma, C., Li, W., Su, X., Huang, S., Chen, R., Zhu, Z., Mao, Z., Han, Y., and Li, M. (2004) SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease Neurosci. Res. 48, 195-202 (Pubitemid 38096401)
8. Kamenecka, T., Jiang, R., Song, X., Duckett, D., Chen, W., Ling, Y. Y., Habel, J., Laughlin, J. D., Chambers, J., Figuera-Losada, M., Cameron, M. D., Lin, L., Ruiz, C. H., and LoGrasso, P. V. (2010) Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors J. Med. Chem. 53, 419-431
9. Przedborski, S., Jackson-Lewis, V., Yokoyama, R., Shibata, T., Dawson, V. L., and Dawson, T. M. (1996) Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity Proc. Natl. Acad. Sci. U.S.A. 93, 4565-4571
10. Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D. K., Ischiropoulos, H., and Przedborski, S. (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinson disease J. Neurosci. 22, 1763-1771 (Pubitemid 35386294)
11. Yang, L., Sugama, S., Mischak, R. P., Kiaei, M., Bizat, N., Brouillet, E., Joh, T. H., and Beal, M. F. (2004) A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo Neurobiol. Dis. 17, 250-259 (Pubitemid 39345780)
12. Crocker, S. J., Smith, P. D., Jackson-Lewis, V., Lamba, W. R., Hayley, S. P., Grimm, E., Callaghan, S. M., Slack, R. S., Melloni, E., Przedborski, S., Robertson, G. S., Anisman, H., Merali, Z., and Park, D. S. (2003) Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease J. Neurosci. 23, 4081-4091 (Pubitemid 36958427)
13. Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., Ford, J. M., Galvin, M., Gerlach, J. L., Grotzfeld, R. M., Herrgard, S., Insko, D. E., Insko, M. A., Lai, A. G., Lelias, J. M., Mehta, S. A., Milanov, Z. V., Velasco, A. M., Wodicka, L. M., Patel, H. K., Zarrinkar, P. P., and Lockhart, D. J. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors Nat. Biotechnol. 23, 329-336 (Pubitemid 41094421)
14. Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., Faraoni, R., Floyd, M., Hunt, J. P., Lockhart, D. J., Milanov, Z. V., Morrison, M. J., Pallares, G., Patel, H. K., Pritchard, S., Wodicka, L. M., and Zarrinkar, P. P. (2008) A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 26, 127-132
15. Bilsland, J., Roy, S., Xanthoudakis, S., Nicholson, D. W., Han, Y., Grimm, E., Hefti, F., and Harper, S. J. (2002) Caspase inhibitors attenuate 1-methyl-4-phenylpyridinium toxicity in primary cultures of mesencephalic dopaminergic neurons J. Neurosci. 22, 2637-2649 (Pubitemid 37465813)
16. Chu, C. T., Zhu, J. H., Cao, G., Signore, A., Wang, S., and Chen, J. (2005) Apoptosis inducing factor mediates caspase-independent 1-methyl-4-phenylpyridinium toxicity in dopaminergic cells J. Neurochem. 94, 1685-1695 (Pubitemid 41324649)
17. Kelder, J., Grootenhuis, P. D., Bayada, D. M., Delbressine, L. P., and Ploemen, J. P. (1999) Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs Pharm. Res. 16, 1514-1519 (Pubitemid 29510546)
18. Martin, Y. C. (2005) A bioavailability score J. Med. Chem. 48, 3164-3170 (Pubitemid 40628036)
19. Gearan, T., Castillo, O. A., and Schwarzschild, M. A. (2001) The parkinsonian neurotoxin, MPP+ induces phosphorylated c-Jun in dopaminergric neurons of mesencephalic cultures Parkinsonism Relat. Disord. 8, 19-22 (Pubitemid 32700266)
20. Han, B. S., Noh, J. S., Gwag, B. J., and Oh, Y. J. (2003) A distinct death mechanism is induced by 1-methyl-4-phenylpyridinium or by 6-hydroxydopamine in cultured rat cortical neurons: degradation and dephosphorylation of tau Neurosci. Lett. 341, 99-102 (Pubitemid 36398479)
21. Kunstle, G., Leist, M., Uhlig, S., Revesz, L., Feifel, R., MacKenzie, A., and Wendel, A. (1997) ICE-protease inhibitors block murine liver injury and apoptosis caused by CD95 or by TNF-α Immunol. Lett. 55, 5-10 (Pubitemid 27117487)
22. Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., and Przedborski, S. (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease Nat. Med. 5, 1403-1409
23. Li, Y., Liu, W., Oo, T. F., Wang, L., Tang, Y., Jackson-Lewis, V., Zhou, C., Geghman, K., Bogdanov, M., Przedborski, S., Beal, M. F., Burke, R. E., and Li, C. (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease Nat. Neurosci. 12, 826-828
24. Emborg, M. E. (2004) Evaluation of animal models of Parkinson's disease for neuroprotective strategies J. Neurosci. Methods 139, 121-143 (Pubitemid 39370838)
25. Deumens, R., Blokland, A., and Prickaerts, J. (2002) Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway Exp. Neurol. 175, 303-317 (Pubitemid 34634286)
26. Kirik, D., Rosenblad, C., and Bjorklund, A. (1998) Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat Exp. Neurol. 152, 259-277 (Pubitemid 28419264)
27. Jiang, R., Duckett, D., Chen, W., Habel, J., Ling, Y. Y., LoGrasso, P., and Kamenecka, T. M. (2007) 3,5-Disubstituted quinolines as novel c-Jun N-terminal kinase inhibitors Bioorg. Med. Chem. Lett. 17, 6378-6382 (Pubitemid 47559120)
28. Kamenecka, T., Habel, J., Duckett, D., Chen, W., Ling, Y. Y., Frackowiak, B., Jiang, R., Shin, Y., Song, X., and LoGrasso, P. (2009) Structure-activity relationships and X-ray structures describing the selectivity of aminopyrazole inhibitors for c-Jun N-terminal kinase 3 (JNK3) over p38 J. Biol. Chem. 284, 12853-12861
29. Shin, Y., Chen, W., Habel, J., Duckett, D., Ling, Y. Y., Koenig, M., He, Y., Vojkovsky, T., LoGrasso, P., and Kamenecka, T. M. (2009) Synthesis and SAR of piperazine amides as novel c-jun N-terminal kinase (JNK) inhibitors Bioorg. Med. Chem. Lett. 19, 3344-3347
30. Walsky, R. L. and Obach, R. S. (2004) Validated assays for human cytochrome P450 activities Drug Metab. Dispos. 32, 647-660 (Pubitemid 38668158)
31. Jackson-Lewis, V. and Przedborski, S. (2007) Protocol for the MPTP mouse model of Parkinson's disease Nat. Protoc. 2, 141-151 (Pubitemid 47044700)
32. Cleren, C., Calingasan, N. Y., Chen, J., and Beal, M. F. (2005) Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity J. Neurochem. 94, 995-1004 (Pubitemid 41170587)